NEONC TECHNOLOGIES HOLDINGS, INC. Accretion Expense
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported Accretion Expense of $1.39 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2025-08-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2025-08-18
- NEONC TECHNOLOGIES HOLDINGS, INC. accretion expense for the quarter ending 2024-06-30 was $0.00.
- NEONC TECHNOLOGIES HOLDINGS, INC. accretion expense for the quarter ending 2024-03-31 was $1.39M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month |
|---|---|---|
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $1.39M 10-Q · filed 2025-08-18 |
| 2024-03-31 | $1.39M 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |